3-chloro-1-cyclohexyl-1-phenyl-propan-1-ol | 77-35-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-chloro-1-cyclohexyl-1-phenyl-propan-1-ol
• 英文别名: 3-Chlor-1-cyclohexyl-1-phenyl-propan-1-ol；1-phenyl-1-cyclohexyl-3-chloro-1-propanol；1-phenyl-1-cyclohexyl-3-chloro-propanol；3-chloro-1-cyclohexyl-1-phenylpropan-1-ol
• CAS: 77-35-0
• 化学式: C₁₅H₂₁ClO
• 分子量: 252.784
• InChiKey: ZERVXURFKJSQMJ-UHFFFAOYSA-N

物化性质

• 沸点：
  396.0±22.0 °C(Predicted)
• 密度：
  1.111±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-chloro-1-cyclohexyl-1-phenyl-propan-1-ol 在 盐酸 、 乙醚 作用下， 以 四氢呋喃 、 氯仿 、 二甲基亚砜 为溶剂， 反应 51.0h， 生成 2-(3-Phenyl-3-cyclohexyl-3-hydroxy)propyl-1H-4,5,6,7-tetrahydrodiazepine hydrochloride
  参考文献：
  名称：

  Nicola; Battista Schiavi; Micheletti, Il Farmaco, 1991, vol. 46, # 4, p. 539 - 553

  摘要：

  DOI：
• 作为产物：
  描述：

  3-氯代苯丙酮 、 环己基溴化镁 生成 3-chloro-1-cyclohexyl-1-phenyl-propan-1-ol
  参考文献：
  名称：

  Synthesis of tricyclamol

  摘要：

  公开号：

  US02826590A1

文献信息

• 1,3-diazocycloalkenes as muscarinic receptor blocking agents
  申请人：Istituto de Angeli

  公开号：US04973592A1

  公开（公告）日：1990-11-27

  New pharmacologically active heterocyclic derivatives as muscarinic receptor blocking agents, useful for the treatment of gastrointestinal disorders, of the following formula ##STR1## wherein the substituents are defined hereinbelow.

  新的药理活性杂环衍生物作为肌胆碱受体阻断剂，用于治疗胃肠道疾病，化学式如下所示 ##STR1## 其中取代基的定义如下。
• New heterocyclic derivatives
  申请人：ISTITUTO DE ANGELI S.p.A.

  公开号：EP0309425A3

  公开（公告）日：1990-06-27

  New pharmacologically active heterocyclic derivatives as muscarinic receptor blocking agents, useful for the treatment of gastrointestinal disorders of the following formula wherein R is hydrogen atom or C₁₋₉ alkyl optionally substituted by 2 or 3 radicals, which may be identical or different from each other, selected from aryl, cycloalkyl, hydroxy and carboxamide; R₁ may be any group indicated for R, or NHR₄, in which R₄ is hydrogen atom, C₁₋₄ alkyl substituted by -OOCR₅, in which R₅ is methyl sub­stituted by 2 or 3 radicals, which may be identical or different from each other, selected from aryl, cycloalkyl and hydroxy, or a cycloalkyl substituted by another cycloalkyl; R₂ is hydrogen atom, C₁₋₄ alkyl, a radical -OOCR₅, in which R₅ is as hereinbefore defined; R₃ is hydrogen atom or C₁₋₄ alkyl; n is 0, 1 or 2 provided that at least one among R, R₁, R₂ and R₃ is different from hydrogen atom.The tautomers of the compounds of formula (I) and acid addition salts thereof, as well as the processes for their preparation and pharmaceu­tical compositions containing them are also described

  新的药理活性杂环衍生物作为肌氨酸受体阻断剂，用于治疗以下化学式中的消化系统疾病，其中R是氢原子或C₁₋₉烷基，可由2或3个基团取代，这些基团可以相同或不同，从芳基、环烷基、羟基和羧酰胺中选择；R₁可以是任何R指示的基团，或NHR₄，在其中R₄是氢原子，C₁₋₄烷基，被-OOCR₅取代，其中R₅是甲基取代的2或3个基团，这些基团可以相同或不同，从芳基、环烷基和羟基中选择，或被另一个环烷基取代的环烷基；R₂是氢原子，C₁₋₄烷基，一个基团-OOCR₅，在其中R₅如前所定义；R₃是氢原子或C₁₋₄烷基；n为0、1或2，前提是R、R₁、R₂和R₃中至少有一个不同于氢原子。该化合物的互变异构体及其酸盐，以及其制备方法和含有它们的药物组合物也被描述。
• New amidino derivatives
  申请人：ISTITUTO DE ANGELI S.p.A.

  公开号：EP0309424A2

  公开（公告）日：1989-03-29

  New pharmacologically active amidino derivatives as muscarinic receptor blocking agents which are useful for the treatment of gastrointestinal disorders of the following formula wherein R represents hydrogen atom, Ci-5 alkyl, aryl, an amino group optionally substituted by one or two C1-5 alkyl; R1 represents hydrogen atom, C1-8 alkyl, aralkyl; A represents Ci-5 alkyl substituted by 2 or 3 radicals, which may be identical or different from each other, selected from aryl, cycloalkyl, carboxamide; or a saturated 6-membered heterocyclic ring containing one nitrogen atom N-substituted by COR2 where R2 is a methyl substituted by 2 or 3 radicals, which may be identical or different from each other, selected from aryl, cycloalkyl, hydroxy; or where R3 is hydrogen atom and R4 is C1-5 alkyl substitued by 2 or 3 radicals, which may be identical or different from each other, selected from aryl, cycloalkyl, carboxamide, or by hydroxy optionally esterified with a cycloalkylcarboxylic acid, or R3 and R4, together with the nitrogen atom to which they are attached, form a saturated 5- to 7-membered heterocyclic ring, optionally containing one or two nitrogen atoms or an endocyclic carboxamido group optionally comprising in its inside -CH2-CH2- or being the heterocyclic ring substituted by a Ci-5 alkyl substituted in turn by 2 or 3 radicals, which may be identical or different from each other, selected from Ci-s alkyl, aryl, cycloalkyl or hydroxy, or byarylalkylene, or by -ORs where Rs is -OCR6 where R6 is methyl substituted by 2 or 3 radicals, which may be identical or different from each other, selected from a saturated or unsaturated C1-5 alkyl, aryl, cycloalkyl, hydroxy Ci-5 alkyl, hydroxy, or unsaturated 6-membered heterocyclic ring, provided that at least one between R and A is amino group or The tautomers and the acid addition salts of these compounds, as well as the process for the preparation of the compounds of formula (I) and pharmaceutical compositions containing them are also described.

  作为毒蕈碱受体阻断剂的新型药理活性脒衍生物，可用于治疗下式所示的胃肠道疾病 式中 R 代表氢原子、C1-5 烷基、芳基、任选被一个或两个 C1-5 烷基取代的氨基； R1 代表氢原子、C1-8 烷基、芳基； A 代表 被 2 个或 3 个基团取代的 Ci-5 烷基，这些基团可以是相同的，也可以是不同的 或彼此不同，选自芳基、环烷基、羧酰胺 或含有一个氮原子的饱和 6 元杂环，该氮原子由 COR2 取代，其中 R2 是由 2 或 3 个基取代的甲基，这些基可以相同或不同，选自芳基、环烷基、羟基；或 其中 R3 是氢原子，R4 是被 2 或 3 个基团取代的 C1-5 烷基，这些基团可以彼此相同或不同，选自芳基、环烷基、羧酰胺，或由羟基任选与环烷基羧酸酯化，或 R3 和 R4 与它们连接的氮原子一起形成饱和的 5-7 元杂环，可任选含有一个或两个氮原子或内环羧酰胺基团，可任选在其内部包含 -CH2- - 或 被一个依次被 2 或 3 个基取代的 Ci-5 烷基取代的杂环，这些基可以彼此相同或不同，选自 Ci-s 烷基、芳基、环烷基或羟基，或芳烷基，或被 -ORs 取代，其中 Rs 为 -OCR6 ，R6 为被 2 或 3 个基取代的甲基、这些基团可以彼此相同或不同，选自饱和或不饱和的 C1-5 烷基、芳基、环烷基、羟基 Ci-5烷基、羟基或不饱和的 6 元杂环，条件是 R 和 A 之间至少有一个基团是氨基，或 此外，还描述了这些化合物的同系物和酸加成盐，以及式（I）化合物和含有它们的药物组合物的制备过程。
• US4973592A
  申请人：——

  公开号：US4973592A

  公开（公告）日：1990-11-27